Pharmaceutical giant Merck has chosen central London as the site of its new headquarters.
The company’s hub will be home to 150 new researchers, and 800 additional staff. Merck’s other European clinical operations will also move to the site from the company’s current headquarters in Hoddesdon, Hertfordshire.
The American pharmaceutical business has started to look at possible locations for the centre, which is set to open in 2020. Merck said it chose London because the city will facilitate its work with researchers both in the UK and in Europe.
“We believe London to be a unique bioscience centre of excellence and a key component of the established golden triangle for academic science of London-Oxford-Cambridge,” said Louise Houson, managing director, Merck in the UK and Ireland.
Merck chose London as part of a life sciences sector deal with the government.
The government will announce four such sector deals today along with its Industrial Strategy White Paper. Other deals have been struck with the construction, artificial intelligence and automotive industries.
The new partnerships with the government are backed by co-investment from the private sector.
Business Secretary Greg Clark said: “We are an open, flexible economy, built on trade and engagement with the world. We have a competitive business environment with a deserved reputation for being a dependable and confident place to do business, thanks to our high standards, respected institutions and a reliable rule of law.”
The Industrial Strategy will also seek to fix the UK’s productivity problems, Clark said.
By Helen Cahill
Source: City AM
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
